Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 19/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 19/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 17/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167644 | 1.00 | ADORA3 (0.62) | ADORA3ADORA2AADORA1ADORA2B | |
| Formic Acid SCHEMBL4897251 | 0.97 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13296838 | 0.95 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5600260 | 0.95 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2289136 | 0.95 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13296874 | 0.95 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL14538873 | 0.95 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL7459932 | 0.92 | ADORA3 (0.64) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13296837 | 0.92 | ADORA3 (0.64) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9970834 | 0.91 | ADORA3 (0.52) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904512-B1 | PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2A RECEPTOR | GLAXO GROUP LTD (GB) | 2012-06-20 | — | — | EP | claimed |
| US-7985740-B2 | anti-inflammatory; (2R,3S,4R,5R)-2-(2-ethyl-2H-tetrazol-5-yl)-5-[2-{[2-(1H-imidazol-4-yl)ethyl]amino}-6-({trans-4-[(2-{[2-(1H-imidazol-4-yl)ethyl]amino}-1H-purin-6-yl)amino]cyclohexyl}amino)-9H-purin-9-yl]tetrahydro-3,4-furandiol; immunosuppressive agents use in treatment of auto-immune diseases | GLAXO GROUP LIMITED (GB) | 2011-07-26 | — | — | US | claimed |
| US-20080214581-A1 | Purine Derivatives as Agonists of the Adenosine A2a Receptor | GLAXO GROUP LIMITED (GB) | 2008-09-04 | — | — | US | claimed |
| EP-1904512-B1 | PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2A RECEPTOR | GLAXO GROUP LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-7985740-B2 | anti-inflammatory; (2R,3S,4R,5R)-2-(2-ethyl-2H-tetrazol-5-yl)-5-[2-{[2-(1H-imidazol-4-yl)ethyl]amino}-6-({trans-4-[(2-{[2-(1H-imidazol-4-yl)ethyl]amino}-1H-purin-6-yl)amino]cyclohexyl}amino)-9H-purin-9-yl]tetrahydro-3,4-furandiol; immunosuppressive agents use in treatment of auto-immune diseases | GLAXO GROUP LIMITED (GB) | 2011-07-26 | — | — | US | disclosed |
| US-7985740-B2 | anti-inflammatory; (2R,3S,4R,5R)-2-(2-ethyl-2H-tetrazol-5-yl)-5-[2-{[2-(1H-imidazol-4-yl)ethyl]amino}-6-({trans-4-[(2-{[2-(1H-imidazol-4-yl)ethyl]amino}-1H-purin-6-yl)amino]cyclohexyl}amino)-9H-purin-9-yl]tetrahydro-3,4-furandiol; immunosuppressive agents use in treatment of auto-immune diseases | GLAXO GROUP LIMITED (GB) | 2011-07-26 | — | — | US | disclosed |
| US-7985740-B2 | anti-inflammatory; (2R,3S,4R,5R)-2-(2-ethyl-2H-tetrazol-5-yl)-5-[2-{[2-(1H-imidazol-4-yl)ethyl]amino}-6-({trans-4-[(2-{[2-(1H-imidazol-4-yl)ethyl]amino}-1H-purin-6-yl)amino]cyclohexyl}amino)-9H-purin-9-yl]tetrahydro-3,4-furandiol; immunosuppressive agents use in treatment of auto-immune diseases | GLAXO GROUP LIMITED (GB) | 2011-07-26 | — | — | US | disclosed |
| US-20080214581-A1 | Purine Derivatives as Agonists of the Adenosine A2a Receptor | GLAXO GROUP LIMITED (GB) | 2008-09-04 | — | — | US | disclosed |
| US-20080214581-A1 | Purine Derivatives as Agonists of the Adenosine A2a Receptor | GLAXO GROUP LIMITED (GB) | 2008-09-04 | — | — | US | disclosed |
| US-20080214581-A1 | Purine Derivatives as Agonists of the Adenosine A2a Receptor | GLAXO GROUP LIMITED (GB) | 2008-09-04 | — | — | US | disclosed |
| EP-1904512-A1 | PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2A RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007009757-A1 | PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2A RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009757-A1 | PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2A RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214581-A1 | Purine Derivatives as Agonists of the Adenosine A2a Receptor | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.